Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

B. W C Tse, M. Volpert, E. Ratther, N. Stylianou, M. Nouri, K. McGowan, M. L. Lehman, S. J. McPherson, M. Roshan-Moniri, M. S. Butler, J. Caradec, C. Y. Gregory-Evans, J. McGovern, R. Das, M. Takhar, N. Erho, M. Alshalafa, E. Davicioni, E. M. Schaeffer, Robert Brian Jenkins & 14 others A. E. Ross, Robert Jeffrey Karnes, R. B. Den, L. Fazli, P. A. Gregory, M. E. Gleave, E. D. Williams, P. S. Rennie, R. Buttyan, J. H. Gunter, L. A. Selth, P. J. Russell, C. C. Nelson, B. G. Hollier

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.Oncogene advance online publication, 16 January 2017; doi:10.1038/onc.2016.482.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Jan 16 2017

Fingerprint

Neuropilin-1
Androgens
Prostate
Mortality
Neoplasms
Prostatic Neoplasms
Therapeutics
Castration
Biomarkers
Neoplasm Metastasis
Prostatectomy
Oncogenes
Small Interfering RNA
Publications
Radiotherapy
Multivariate Analysis
Lymph Nodes
Staining and Labeling

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. / Tse, B. W C; Volpert, M.; Ratther, E.; Stylianou, N.; Nouri, M.; McGowan, K.; Lehman, M. L.; McPherson, S. J.; Roshan-Moniri, M.; Butler, M. S.; Caradec, J.; Gregory-Evans, C. Y.; McGovern, J.; Das, R.; Takhar, M.; Erho, N.; Alshalafa, M.; Davicioni, E.; Schaeffer, E. M.; Jenkins, Robert Brian; Ross, A. E.; Karnes, Robert Jeffrey; Den, R. B.; Fazli, L.; Gregory, P. A.; Gleave, M. E.; Williams, E. D.; Rennie, P. S.; Buttyan, R.; Gunter, J. H.; Selth, L. A.; Russell, P. J.; Nelson, C. C.; Hollier, B. G.

In: Oncogene, 16.01.2017.

Research output: Contribution to journalArticle

Tse, BWC, Volpert, M, Ratther, E, Stylianou, N, Nouri, M, McGowan, K, Lehman, ML, McPherson, SJ, Roshan-Moniri, M, Butler, MS, Caradec, J, Gregory-Evans, CY, McGovern, J, Das, R, Takhar, M, Erho, N, Alshalafa, M, Davicioni, E, Schaeffer, EM, Jenkins, RB, Ross, AE, Karnes, RJ, Den, RB, Fazli, L, Gregory, PA, Gleave, ME, Williams, ED, Rennie, PS, Buttyan, R, Gunter, JH, Selth, LA, Russell, PJ, Nelson, CC & Hollier, BG 2017, 'Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality', Oncogene. https://doi.org/10.1038/onc.2016.482
Tse, B. W C ; Volpert, M. ; Ratther, E. ; Stylianou, N. ; Nouri, M. ; McGowan, K. ; Lehman, M. L. ; McPherson, S. J. ; Roshan-Moniri, M. ; Butler, M. S. ; Caradec, J. ; Gregory-Evans, C. Y. ; McGovern, J. ; Das, R. ; Takhar, M. ; Erho, N. ; Alshalafa, M. ; Davicioni, E. ; Schaeffer, E. M. ; Jenkins, Robert Brian ; Ross, A. E. ; Karnes, Robert Jeffrey ; Den, R. B. ; Fazli, L. ; Gregory, P. A. ; Gleave, M. E. ; Williams, E. D. ; Rennie, P. S. ; Buttyan, R. ; Gunter, J. H. ; Selth, L. A. ; Russell, P. J. ; Nelson, C. C. ; Hollier, B. G. / Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. In: Oncogene. 2017.
@article{1a644e60acb34b33b2e94373d4d2a4b4,
title = "Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality",
abstract = "Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.Oncogene advance online publication, 16 January 2017; doi:10.1038/onc.2016.482.",
author = "Tse, {B. W C} and M. Volpert and E. Ratther and N. Stylianou and M. Nouri and K. McGowan and Lehman, {M. L.} and McPherson, {S. J.} and M. Roshan-Moniri and Butler, {M. S.} and J. Caradec and Gregory-Evans, {C. Y.} and J. McGovern and R. Das and M. Takhar and N. Erho and M. Alshalafa and E. Davicioni and Schaeffer, {E. M.} and Jenkins, {Robert Brian} and Ross, {A. E.} and Karnes, {Robert Jeffrey} and Den, {R. B.} and L. Fazli and Gregory, {P. A.} and Gleave, {M. E.} and Williams, {E. D.} and Rennie, {P. S.} and R. Buttyan and Gunter, {J. H.} and Selth, {L. A.} and Russell, {P. J.} and Nelson, {C. C.} and Hollier, {B. G.}",
year = "2017",
month = "1",
day = "16",
doi = "10.1038/onc.2016.482",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

AU - Tse, B. W C

AU - Volpert, M.

AU - Ratther, E.

AU - Stylianou, N.

AU - Nouri, M.

AU - McGowan, K.

AU - Lehman, M. L.

AU - McPherson, S. J.

AU - Roshan-Moniri, M.

AU - Butler, M. S.

AU - Caradec, J.

AU - Gregory-Evans, C. Y.

AU - McGovern, J.

AU - Das, R.

AU - Takhar, M.

AU - Erho, N.

AU - Alshalafa, M.

AU - Davicioni, E.

AU - Schaeffer, E. M.

AU - Jenkins, Robert Brian

AU - Ross, A. E.

AU - Karnes, Robert Jeffrey

AU - Den, R. B.

AU - Fazli, L.

AU - Gregory, P. A.

AU - Gleave, M. E.

AU - Williams, E. D.

AU - Rennie, P. S.

AU - Buttyan, R.

AU - Gunter, J. H.

AU - Selth, L. A.

AU - Russell, P. J.

AU - Nelson, C. C.

AU - Hollier, B. G.

PY - 2017/1/16

Y1 - 2017/1/16

N2 - Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.Oncogene advance online publication, 16 January 2017; doi:10.1038/onc.2016.482.

AB - Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies, where it promotes tumor angiogenesis. However, non-angiogenic roles of NRP1 in tumor progression remain poorly characterized. In this study, we define NRP1 as an androgen-repressed gene whose expression is elevated during the adaptation of prostate tumors to androgen-targeted therapies (ATTs), and subsequent progression to metastatic castration-resistant prostate cancer (mCRPC). Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that NRP1 regulates the mesenchymal phenotype of mCRPC cell models and the invasive and metastatic dissemination of tumor cells in vivo. In patients, immunohistochemical staining of tissue microarrays and mRNA expression analyses revealed a positive association between NRP1 expression and increasing Gleason grade, pathological T score, positive lymph node status and primary therapy failure. Furthermore, multivariate analysis of several large clinical prostate cancer (PCa) cohorts identified NRP1 expression at radical prostatectomy as an independent prognostic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortality. This study identifies NRP1 for the first time as a novel androgen-suppressed gene upregulated during the adaptive response of prostate tumors to ATTs and a prognostic biomarker of clinical metastasis and lethal PCa.Oncogene advance online publication, 16 January 2017; doi:10.1038/onc.2016.482.

UR - http://www.scopus.com/inward/record.url?scp=85009818595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009818595&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.482

DO - 10.1038/onc.2016.482

M3 - Article

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -